Effects of Argon Laser Iridotomy on the Corneal Endothelium of Pigmented Rabbit Eyes

염지현,허정화,김효명,송종석 대한안과학회 2014 Korean Journal of Ophthalmology Vol.28 No.1

Purpose: In Asian countries, laser iridotomy for the treatment of angle-closure glaucoma is a common cause ofbullous keratopathy, which may be associated with a shallow anterior chamber and dark iris pigmentation inAsians. Several cases of corneal decompensation after argon laser iridotomy have been reported. In the presentstudy, we evaluated the harmful effects of argon laser iridotomy on the corneal endothelium. Methods: Argon laser iridotomy was performed on the right eyes of pigmented rabbits. Changes in cornealthickness and endothelial cell density after laser iridotomy were evaluated. Terminal deoxynucleotidyl transferasedUTP nick end labeling (TUNEL) was performed for assessment of corneal endothelial cell apoptosis. Combined staining with alizarin red and trypan blue, as well as a live/dead cell assay, were performed for evaluationof damage to the corneal endothelium induced by laser iridotomy. Results: Corneal thickness did not change immediately after laser iridotomy; however, a significant increasewas observed 24 hours after iridotomy (p = 0.001). The endothelial cell density of laser-treated eyes four daysafter laser iridotomy was significantly decreased compared with control eyes (p < 0.001). TUNEL stainingshowed many TUNEL-positive cells in the corneal endothelium and corneal stroma. No endothelial trypanblue-stained cell nuclei were observed after laser iridotomy; however, several large endothelial cells with damagedmembrane integrity were observed. The live/dead cell assay clearly showed a large number of deadcells stained red in several areas throughout the entire corneal button 24 hours after iridotomy. Conclusions: Argon laser iridotomy induces corneal endothelial cell apoptosis in pigmented rabbit eyes, resultingin decreased endothelial cell density.

국제표준에 기반한 전자증례기록지의 생성

염지현,정수아,김혁만 한국정보과학회 2014 데이타베이스 연구 Vol.30 No.3

In this paper, we develop a system that generates electronic case report forms (CRFs) conforming to the CDASH, SDTM and ODM standards developed by the CDISC consortium. With the system, users edits CRFs using the CDISC metadata database which seamlessly integrates metadata provided by both the CDASH and SDTM standards, and stores the edited CRFs into the CRF database based on the ODM standard. The proposed system also generates SDTM raw datasets without user intervention. The system provides user interfaces with which users can fast and easily edit CRFs without prior knowledge or understanding of the CDISC standards. This will greatly reduce setup times of clinical trials. 본 논문에서는 CDISC에서 개발한 CDASH, SDTM 및 ODM 국제표준을 준수하는 전자증례기록지를 생성하는 시스템을 개발한다. 개발한 시스템은 CDASH와 SDTM 표준을 통합한 CDISC 메타데이터 데이터베이스를 사용하여 증례기록지를 편집하고, ODM 표준에 기반한 증례기록지 데이터베이스에 편집한 내용을 저장한다. 개발한 시스템은 편집한 증례기록지뿐만 아니라 원시 데이터셋도 CDASH 및 SDTM 표준에 따라 데이터를 유지한다. 또한 본 시스템은 증례기록지의 콘텐츠 및 양식을 쉽고 편하게 편집하는 사용자 인터페이스를 제공한다. 사용자는 CDISC 표준에 대한 지식이 없어도 CDISC 표준에 기반한 증례기록지를 편집하고 생성할 수 있으며, 이를 통해 임상시험 셑업 기간을 크게 단축할 수 있다.

CDISC 표준에 기반한 임상시험 데이터베이스의 설계

염지현,정수아,김혁만 한국정보과학회 2014 데이타베이스 연구 Vol.30 No.1

In this paper, a database for clinical trials which conforms to the standards developed by CDISCis proposed. The proposed database consists of CDISC metadata and CRF database. The CDISCmetadata database allows mapping CDASH standard variables of CRFs to SDTM ones of rawdatasets. The CRF database decomposes CRFs into data items specified in ODM, and stores theitems. By utilizing the databases, it is possible to maintain CRFs and their raw datasets to generateODM XML that describes CRFs. The ODM XML will be transformed to HTML or PDF files byapplying XSLT. 본 논문에서는 CDISC에서 개발한 국제표준을 준수하는 임상시험 데이터베이스를 설계한다. 설계한 임상시험데이터베이스는 CDISC 메타데이터 데이터베이스와 증례기록지 데이터베이스로 구성된다. CDISC 메타데이터 데이터베이스는 CDASH 표준과 SDTM 표준을 통합하여, 증례기록지의 데이터 항목을 원시 데이터셑의 변수에 매핑한다. 증례기록지 데이터베이스는 ODM 표준에서 정의한 구조를 이용하여, 증례기록지의 내용을 분해하여 저장한다. 설계한 임상시험 데이터베이스는 CDISC 표준에 따른 증례기록지와 원시 데이터셑을 동시에 유지할 수 있다. 또한,증례기록지를 ODM XML 파일로 생성 가능하며, 이 파일은 XSLT 변환을 거쳐 HTML 파일로 화면에 디스플레이되거나 PDF 파일로 출력될 수 있다.

SH-SY5Y Human Neuroblastoma Cell에서 에스트로겐의 신경세포 보호효과에 대한 기전

염지현,김희,홍현석,방오영,허균,묵인희 대한치매학회 2003 Dementia and Neurocognitive Disorders Vol.2 No.1

Apoptosis is one major mechanism underlying neuronal cell death in degenerative diseases in the central nervous system. Previous studies have shown that estrogen has neuroprotective effects in several neuronal cell death model systems. In the present study, we established a staurosporine-induced apoptotic neuronal cell death system with human SH-SY5Y cell line. 17b-estradiol(E2) blocked staurosporine-induced apoptosis of SH-SY5Y cells as revealed by MTT as well as LDH assay. The cells showed typical DNA fragmentation at 4 h and 8 h following staurosporine treatment, which was attenuated by E2 pretreatment. Staurosporine-induced chromatin condensation was also reduced by E2 treatment. Because apoptotic stimuli are known to induce caspase-3 activation and PARP cleavage, we examined whether E2 blocks these processes. E2 markedly attenuated staurosporine-induced casapase-3 activation and PARP cleavage. This study shows that E2 blocks staurosporine-induced apoptosis in SH-SY5Y human neuroblastoma cells, suggesting that E2 is a neuroprotective agent that may be used for the treatment of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

24개월 이상 선천 코눈물관막힘 환아의 단계적 탐침술을 동반한 단, 상하누소관 실리콘관 효과

염지현,이화,장민욱,백세현,이태수,Jie Hyun Youm,Hwa Lee,Min Wook Jang,Se Hyun Baek,Tae Soo Lee 대한안과학회 2013 대한안과학회지 Vol.54 No.11

Purpose: The clinical effectiveness of monocanalicular or bicanalicular intubation with sequential probing was evaluated in patients over the age of 24 months with congenital nasolacrimal duct obstruction. Methods: Patients over 24 months of age with congenital nasolacrimal duct obstruction who underwent monocanalicular intubation with sequential probing (19 patients, 20 eyes) or bicanalicular intubation with sequential probing (22 patients, 22 eyes) were studied. Success rates and complications were evaluated. Silicone tube was removed 6 months after surgery. Success was defined as no epiphora and no retention on fluorescein dye disappearance test. Results: The success rate was 95.0% (19 eyes / 20 eyes) in the monocanalicular intubation group and complications included 7 cases of early tube dislodgement, which achieved successful outcome. The success rate was 82.6% (19 eyes / 22 eyes) in the bicanalicular intubation group and complications included 4 cases of punctal slitting, and 3 cases of tube extrusion. The success and complication rates were not significantly different between the 2 groups (p = 0.608, p = 1.000, respectively). Conclusions: In congenital nasolacrimal duct obstruction, the monocanalicular tube intubation group had similar success and complication rates to the bicanalicular tube intubation group. Silicone tube maintenance for 2 months in the monocanalicular group and for 3 months in the bicanalicular group was sufficient. J Korean Ophthalmol Soc 2013;54(11):1635-1640

Intracellular delivery of recombinant proteins via gold nanoparticle– DNA aptamer composites is independent of the protein physicochemical properties and cell type

염지현,주민주,이보은,Keun P. Kim,하남철,박윤경,배지현,이강석 한국공업화학회 2017 Journal of Industrial and Engineering Chemistry Vol.45 No.-

Here, we report that the gold nanoparticle–DNA aptamer (AuNP–Apt) conjugate-based system canefficiently deliver recombinant proteins into mammalian cells in a manner independent of their size,isoelectric point, and cellular localization. Additionally, AuNP–Apt system-assisted protein delivery canbe effective on primary and stem cells, indicating that its use is not limited to fast-dividing cells. Wefurther show that the intravenously administered AuNP–Apt system can deliver proteins into rat organs. Ourfindings show that this system can serve as a simple, efficient, and versatile platform for the deliveryof recombinant proteins into mammalian living systems.

A case of minimal change disease in a patient with primary Sjogren syndrome

염지현,김경민,최윤정,류완희,강경표 대한내과학회 2018 대한내과학회 추계학술대회 Vol.2018 No.1

Multiscale Chirality of Inorganic Materials

염지현 한국공업화학회 2021 한국공업화학회 연구논문 초록집 Vol.2021 No.0

맥킨타이어의 덕론을 통해 본 태권도 교육

염지현,안용규 한국스포츠학회 2014 한국스포츠학회지 Vol.12 No.1

다국적 임상시험 지원을 위한 CDISC 표준의 확장

염지현(Jihyeon Yeom),최인영(Inyoung Choi),김석일(Sukil Kim),김혁만(Hyeokman Kim) 한국정보과학회 2009 정보과학회 컴퓨팅의 실제 논문지 Vol.15 No.8

CDISC 컨소시엄에서는 임상시험에서의 비효율적인 데이터 처리 과정을 개선하기 위해, 플랫폼에 독립적인 임상시험 데이터 표준을 정의하였다. 그러나, CDISC 표준은 여러 나라의 여러 기관이 함께 참여하는 다국가 임상시험에서 발생하는 임상시험 데이터를 다국어로 표현하는 방법에 많은 제약을 갖고 있다. 특히, CDISC가 제정한 표준 중 임상시험 데이터의 콘텐츠 및 포맷에 해당하는 SDTM(Study Data Tabulation Model)과 ODM(Operational Data Model)에서의 다국어 지원이 매우 미비하다. 본 논문은 CDISC의 SDTM과 ODM에서의 언어 설정에 대한 문제점을 해결하기 위해, SDTM과 ODM 표준의 확장을 제안한다. 이를 위해 SDTM에서는 다국어 지원을 위한 새로운 도메인을 설계하였고, ODM에서는 ODM의 확장 스키마를 서브타이핑 방법으로 구현하였다. 확장 SDTM과 ODM을 기반으로 임상시험 데이터를 처리하면, 다국가 임상시험이 수행되는 경우 다국어로 표현된 임상시험 데이터도 효율적으로 처리할 수 있다. Clinical Data Interchange Standards Consortium (CDISC) developed global and platformindependent data standards to improve ineffective processes of clinical trial studies. Regardless of its objective toward global cooperation, the current version of the CDISC standard cannot describe clinical trial data in various languages for multi-national investigators or reviewers. This problem applies not only to tabulated datasets in Study Data Tabulation Model (SDTM) but also to extensible markup language representation of the datasets in Operational Data Model (ODM) instances. In order to address this issue, we propose to extend the current version of SDTM and ODM to collect clinical data for multi-national clinical trials. SDTM needs to have new special-purpose domain for multi-language representation purpose. Additionally, ODM is recommended to extend its XML schema using subtyping or type inheritance mechanism respectively. Our extension of SDTM and ODM enable to represent any granule of study data tabulation model or XML data entities to describe in efficient languages. This result will contribute to collect multi-language data easily for multi-national clinical trials.